Abstract:Abstract Background In the phase 3 POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, was well-tolerated and efficacious over 1 year in patients with psoriasis. Objective Evaluate deucravacitinib safety and efficacy over 2 years in patients participating in the phase 3 trials. Methods In the POETYK long-term extension (LTE), an ongoing, phase 3b, open-label trial, adults with moderate to severe plaque psoriasis who completed PSO-1 or PSO-2 receive deucravacitinib 6 mg once daily. Safety was assessed via adverse events (AEs) and laboratory parameter abnormalities. Efficacy endpoints, including ≥75% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment (sPGA) score of 0/1 (clear/almost clear), were evaluated in patients originally randomized to deucravacitinib, patients crossing over from placebo at Week 16, and patients achieving PASI 75 at Week 24 (peak efficacy). Results At data cutoff (October 1, 2021), 1519 patients had received ≥1 dose of deucravacitinib; 79.0% and 39.9% had ≥52 weeks and ≥104 weeks, respectively, of total deucravacitinib exposure. Exposure-adjusted incidence rates (EAIRs) per 100 person-years were similar at 1 year and 2 years, respectively, for any AEs (229.2 vs 154.4), serious AEs (5.7 vs 6.1), discontinuations (4.4 vs 2.8), deaths (0.2 vs 0.4), serious infections (1.7 vs 2.6), herpes zoster (0.9 vs 0.8), major adverse cardiovascular events (0.3 vs 0.4), venous thromboembolic events (0.2 vs 0.1), and malignancies (1.0 vs 0.9). EAIRs for COVID-19 infections were higher at 2 years than at 1 year (5.1 vs 0.5) due to the peak of the global COVID-19 pandemic occurring during the LTE. No clinically meaningful changes from baseline or trends were observed over 2 years in haematologic, chemistry, or lipid parameters. Clinical responses were maintained in patients receiving continuous deucravacitinib treatment from baseline (PASI 75: Week 52, 72.4%; Week 112, 79.7%; sPGA 0/1: Week 52, 57.9%; Week 112, 61.1% [as observed]). Responses at Week 52 were also maintained in placebo crossovers and in Week 24 PASI 75 responders. Conclusions Deucravacitinib maintained efficacy and demonstrated consistent safety with no new safety signals observed through 2 years. (ClinicalTrials.gov identifier: NCT04036435).

Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis

Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis

Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis

Deucravacitinib for the Treatment of Psoriatic Disease

SOTYKTUTM (Deucravacitinib 6-mg Tablets)- A New Agent for the Management of Adult Plaque Psoriasis

Deucravacitinib in the treatment of psoriasis

Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis

Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients from China Mainland, Taiwan, and South Korea with Moderate to Severe Plaque Psoriasis: a Phase 3 Randomized Clinical Trial

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

TYK2 inhibition: changing the treatment landscape for psoriasis?

Deucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials